Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma

BACKGROUND: Most Hodgkin lymphomas (HL) can be cured with current strategies. However, one-third of the cases do not respond or relapse and need salvage regimens. We report the results of a retrospective study using the gemcitabine and oxaliplatinum (GemOx) regimen. METHODS: Patients who relapsed or...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Gutierrez, Antonio, Rodriguez, Jose, Martinez-Serra, Jordi, Gines, Jordi, Paredes, Pilar, Garcia, Florencia, Vercher, Javier, Balanzat, Josep, del Campo, Raquel, Galan, Pilar, Morey, Miguel, Sampol, Antonia, Novo, Andres, Bento, Leyre, García, Lucia, Bargay, Joan, Besalduch, Joan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2014
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4235490/
https://ncbi.nlm.nih.gov/pubmed/25419147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S70264
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller